Down another 6% in a week! So will the GSK share price ever recover?
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic Alliances, and New Vaccine Launches
GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a ...
GlaxoSmithKline Sell Rating Justified by Earnings Concerns and Market Challenges
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
Is the GSK share price the biggest bargain on the FTSE 100?
The GSK share price is nearly 10% off its 52-week high, and this Fool is keen to take a closer look. Could it be a stock for ...
GlaxoSmithKline (GSK) Gets a Sell from J.P. Morgan
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
Yahoo Finance13d
With GSK’s share price down 9%, is it time for me to buy more on the dip?
GSK’s (LSE: GSK) share price is 9% down from its 15 May 12-month traded high of £18.19. This compounds the stock’s already extreme undervaluation against its competitors apparent to me beforehand.
Zacks.com on MSN9d
BioNTech (BNTX) Stock Jumps 5.8%: Will It Continue to Soar?
BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...
GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in ...
Seeking Alpha9d
Fulcrum downgraded after setback for lead program (update)
Fulcrum Therapeutics (NASDAQ:FULC) announced Thursday after its lead program for protein kinase inhibitor losmapimod, in-licensed from GSK ... stock to neutral from outperform, leaving its price ...